- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - pharmaceuticals
- ALKEM LABORATORIES - TEVA PHARMA (Israel)
ALKEM LABORATORIES vs TEVA PHARMA (Israel) - Comparison Results
TEVA PHARMA (Israel)
Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
Financials
 ALKEM LABORATORIES  TEVA PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ALKEM LABORATORIES Mar-16 |
TEVA PHARMA Dec-13 |
ALKEM LABORATORIES/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,589 | 2,913 | - | |
| Low | Rs | 1,232 | 2,530 | - | |
| Sales per share (Unadj.) | Rs | 417.5 | 1,671.6 | - | |
| Earnings per share (Unadj.) | Rs | 56.3 | 104.4 | - | |
| Cash flow per share (Unadj.) | Rs | 64.7 | 239.5 | - | |
| Dividends per share (Unadj.) | Rs | 12.70 | 91.41 | - | |
| Dividend yield (eoy) | % | 0.9 | 3.4 | 26.8% | |
| Book value per share (Unadj.) | Rs | 292.9 | 1,856.8 | - | |
| Shares outstanding (eoy) | m | 119.57 | 848.00 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 3.4 | 1.6 | 207.5% | |
| Avg P/E ratio | x | 25.1 | 26.1 | 96.1% | |
| P/CF ratio (eoy) | x | 21.8 | 11.4 | 191.9% | |
| Price / Book Value ratio | x | 4.8 | 1.5 | 328.5% | |
| Dividend payout | % | 22.6 | 87.5 | 25.8% | |
| Avg Mkt Cap | Rs m | 168,653 | 2,307,764 | 7.3% | |
| No. of employees | `000 | NA | 44.9 | 0.0% | |
| Total wages/salary | Rs m | 9,171 | 0 | - | |
| Avg. sales/employee | Rs Th | NM | 31,538.8 | - | |
| Avg. wages/employee | Rs Th | NM | 0 | - | |
| Avg. net profit/employee | Rs Th | NM | 1,970.2 | - | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 49,915 | 1,417,511 | 3.5% | |
| Other income | Rs m | 1,645 | 0 | - | |
| Total revenues | Rs m | 51,561 | 1,417,511 | 3.6% | |
| Gross profit | Rs m | 8,482 | 388,186 | 2.2% | |
| Depreciation | Rs m | 1,006 | 114,579 | 0.9% | |
| Interest | Rs m | 671 | 27,842 | 2.4% | |
| Profit before tax | Rs m | 8,451 | 245,765 | 3.4% | |
| Minority Interest | Rs m | -114 | 1,116 | -10.2% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | -161,331 | 0.0% | |
| Tax | Rs m | 1,606 | -3,001 | -53.5% | |
| Profit after tax | Rs m | 6,731 | 88,551 | 7.6% | |
| Gross profit margin | % | 17.0 | 27.4 | 62.1% | |
| Effective tax rate | % | 19.0 | -1.2 | -1,556.5% | |
| Net profit margin | % | 13.5 | 6.2 | 215.9% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 27,062 | 957,382 | 2.8% | |
| Current liabilities | Rs m | 15,324 | 834,918 | 1.8% | |
| Net working cap to sales | % | 23.5 | 8.6 | 272.2% | |
| Current ratio | x | 1.8 | 1.1 | 154.0% | |
| Inventory Days | Days | 67 | 91 | 73.2% | |
| Debtors Days | Days | 41 | 96 | 43.0% | |
| Net fixed assets | Rs m | 12,610 | 462,990 | 2.7% | |
| Share capital | Rs m | 239 | 3,489 | 6.9% | |
| Net worth | Rs m | 35,027 | 1,574,586 | 2.2% | |
| Long term debt | Rs m | 1,212 | 724,805 | 0.2% | |
| Total assets | Rs m | 54,387 | 3,239,467 | 1.7% | |
| Interest coverage | x | 13.6 | 9.8 | 138.4% | |
| Debt to equity ratio | x | 0 | 0.5 | 7.5% | |
| Sales to assets ratio | x | 0.9 | 0.4 | 209.7% | |
| Return on assets | % | 13.6 | 3.6 | 378.8% | |
| Return on equity | % | 19.2 | 5.6 | 341.7% | |
| Return on capital | % | 24.9 | 4.9 | 504.1% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 7,259 | 225,878 | 3.2% | |
| From Investments | Rs m | 1,864 | -80,038 | -2.3% | |
| From Financial Activity | Rs m | -9,273 | -270,956 | 3.4% | |
| Net Cashflow | Rs m | -150 | -125,116 | 0.1% | |
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 69.78 Rs / USD
Compare ALKEM LABORATORIES With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare ALKEM LABORATORIES With: SUN PHARMA NOVARTIS IPCA LABS STRIDES SHASUN LTD UNICHEM LAB
|
| |
Today's Market
Of Rupee's Fall, China's Investment Growth, and Top Stocks in Focus Today(Pre-Open)
On Tuesday, Indian share markets ended the day on a positive note with gains were largely seen in the healthcare sector, realty sector and energy sector.
Related Views On News
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
Eris Lifesciences Limited (IPO)
Jun 15, 2017Exposure to high margin specialty products offers promising growth prospects.
Laurus Labs Ltd (IPO)
Dec 6, 2016Equitymaster analyses Initial Public Offering (IPO) of Laurus Labs, one of the leading supplier of APIs for ARVs and Hepatitis C.
More Views on NewsMost Popular
How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)
Aug 3, 2018In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.
The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)
Aug 3, 2018This price pattern can help you identify stocks on the verge of a turnaround.
Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)
Aug 3, 2018To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?
Why HDFC Equity Fund Disappointed Its Investors(Outside View)
Aug 9, 2018Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.
HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)
Aug 8, 2018PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.
More|
| |
ALKEM LABORATORIES SHARE PRICE
Aug 14, 2018 (Close)
TRACK ALKEM LABORATORIES
- Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ALKEM LABORATORIES
ALKEM LABORATORIES - FRESENIUS KABI ONCO. COMPARISON
COMPARE ALKEM LABORATORIES WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.